Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa

NCT06079281 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypophosphatasia

Interventions

DRUG: ALXN1850
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.